highly potent and selective PPAR-α agonist known as LY518674 in patients with lipid disorders. In the first study, 309 patients with atherogenic dyslipidemia (mean age 54.2 years, 68.9% men ...

The following is a summary of “Metabolic complications and clinical outcomes of non-functioning adrenal incidentalomas: a ...

Triglycerides are a vital source of energy, but when levels become dangerously high, they can lead to serious health ...

PSORIASIS is a chronic inflammatory skin disease influenced by both genetic and environmental factors, affecting ...

With this vision, Sukh Dev and his team delivered powerful solutions to treat lipid disorders and minimise the risk of early pregnancy loss, and also found cures for parasites plaguing livestock ...

The highest dose of AstraZeneca’s small molecule halved levels of a type of “bad” cholesterol after 12 weeks, hitting the ...

A unique form of treatment has the ability to filter the LDL out of a patient's bloodstream. However, it is only available at ...

This radical new way of the regulation of chloride co-transporter activity linked with membrane lipid expression suggests new therapeutical strategies to treat epilepsy. By increasing the general ...

Her team is a member of the Research Program Unit, Research Program of Clinical and Molecular Metabolism at the University of Helsinki. Her research team has a focus on lipid lipoprotein metabolism in ...